Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 07/30/26
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental VitiligoBusiness Wire • 07/30/26
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionBusiness Wire • 07/29/26
Boomers Are Buying 5 Quality High-Yield Stocks at Big Discounts Hand Over Fist24/7 Wall Street • 07/29/26
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/28/26
Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too FarSeeking Alpha • 07/27/26
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.The Motley Fool • 07/25/26
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight AnswerThe Motley Fool • 07/23/26
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer UseZacks Investment Research • 07/23/26
FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate CancerBusiness Wire • 07/22/26
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% laterReuters • 07/21/26
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings SeasonZacks Investment Research • 07/21/26
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 07/20/26
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?The Motley Fool • 07/20/26
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right NowThe Motley Fool • 07/19/26
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?The Motley Fool • 07/18/26